Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Moxifloxacin hydrochloride
Drug ID BADD_D01502
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status approved; investigational
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D00874
MeSH ID D000077266
PubChem ID 101526
TTD Drug ID D0ZV0Z
NDC Product Code 48943-0025; 55111-064; 58032-0131; 40032-034; 60429-893; 50370-0001; 51927-4833; 51991-943; 72789-037; 29967-0005; 49574-522; 63323-850; 65862-627; 0093-7387; 50090-4100; 70518-3738; 51927-0167; 0781-7135; 49587-106; 50090-4058; 66298-8507; 67296-1616; 67457-323; 72789-038; 13668-201; 0078-0939; 65862-603; 68084-722; 0832-1410; 50268-576; 51927-0089; 57237-156
UNII C53598599T
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H25ClFN3O4
CAS Registry Number 186826-86-8
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Oral fungal infection11.03.05.010; 07.05.07.009--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Sensation of foreign body08.01.09.002--Not Available
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Urine analysis abnormal13.13.02.008--Not Available
Renal impairment20.01.03.010--Not Available
Cystitis noninfective20.03.02.001--
Infusion site extravasation12.07.05.008; 08.02.05.007--
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Ventricular tachyarrhythmia02.03.04.012--Not Available
Liver injury12.01.17.012; 09.01.07.022--Not Available
Adverse reaction08.06.01.018--Not Available
Acute kidney injury20.01.03.016--
Acute yellow liver atrophy09.01.07.026--Not Available
Candida infection11.03.03.021--
Multiple organ dysfunction syndrome08.01.03.057--
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Hypersensitivity pneumonitis10.01.03.056; 22.01.01.027--Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 14th Page    First    Pre   14    Total 14 Pages